파킨슨병의 생물표지자: 임상 및 생화학 생물표지자

키워드

참고문헌 (96)

1. Postuma RB, "MDS clinical diagnostic criteria for Parkinson’s disease", Mov Disord, 30, pp.1591~1601 (2015)
2. Postuma RB, "Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease", Mov Disord, 27, pp.617~626 (2012)
3. Meara J, "Accuracy of diagnosis in patients with presumed Parkinson’s disease", Age Ageing, 28, pp.99~102 (1999)
4. Chen-Plotkin AS, "Finding useful biomarkers for Parkinson’s disease", Sci Transl Med, 10, pp.eaam6003~ (2018)
5. Mahlknecht P, "The concept of prodromal Parkinson’s disease", J Parkinsons Dis, 5, pp.681~697 (2015)
6. Kim YE, "Clinical implication of REM sleep behavior disorder in Parkinson’s disease", J Parkinsons Dis, 4, pp.237~244 (2014)
7. Kim YE, "REM sleep behavior disorder in early Parkinson’s disease predicts the rapid dopaminergic denervation", Parkinsonism Relat Disord, 80, pp.120~126 (2020)
8. Braak H, "Invited article: nervous system pathology in sporadic Parkinson disease", Neurology, 70, pp.1916~1925 (2008)
9. Lebouvier T, "Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms", PLoS One, 5, pp.e12728~ (2010)
10. Wakabayashi K, "Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses", Acta Neuropathol, 76, pp.217~221 (1988)
11. Cheon SM, "Nonmotor symptoms of Parkinson’s disease: prevalence and awareness of patients and families", Parkinsonism Relat Disord, 14, pp.286~290 (2008)
12. Martinez-Martin P, "Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients", Mov Disord, 22, pp.1623~1629 (2007)
13. Abbott RD, "Frequency of bowel movements and the future risk of Parkinson’s disease", Neurology, 57, pp.456~462 (2001)
14. Haikal C, "Microbiome changes: an indicator of Parkinson’s disease?", Transl Neurodegener, 8, pp.38~ (2019)
15. Heintz-Buschart A, "The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder", Mov Disord, 33, pp.88~98 (2018)
16. Doty RL, "Olfaction in Parkinson’s disease", Parkinsonism Relat Disord, 13(Suppl 3), pp.S225~S228 (2007)
17. Goldman JG, "Premotor and nonmotor features of Parkinson’s disease", Curr Opin Neurol, 27, pp.434~441 (2014)
18. Ross GW, "Association of olfactory dysfunction with risk for future Parkinson’s disease", Ann Neurol, 63, pp.167~173 (2008)
19. Jennings D, "Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study", Neurology, 83, pp.1739~1746 (2014)
20. Schuurman AG, "Increased risk of Parkinson’s disease after depression: a retrospective cohort study", Neurology, 58, pp.1501~1504 (2002)
21. Schapira AH, "Etiology and pathogenesis of Parkinson disease", Neurol Clin, 27, pp.583~603 (2009)
22. Barbour R, "Red blood cells are the major source of alpha-synuclein in blood", Neurodegener Dis, 5, pp.55~59 (2008)
23. Bougea A, "Plasma alpha-synuclein levels in patients with Parkinson’s disease:a systematic review and meta-analysis", Neurol Sci, 40, pp.929~938 (2019)
24. El-Agnaf OM, "Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease", FASEB J, 20, pp.419~425 (2006)
25. Wang X, "Detection of alpha-synuclein oligomers in red blood cells as a potential biomarker of Parkinson’s disease", Neurosci Lett, 599, pp.115~119 (2015)
26. Parnetti L, "CSF and blood biomarkers for Parkinson’s disease", Lancet Neurol, 18, pp.573~586 (2019)
27. Zhou B, "The diagnostic and differential diagnosis utility of cerebrospinal fluid alpha-synuclein levels in Parkinson’s disease: a meta-analysis", Parkinsons Dis, 2015, pp.567386~ (2015)
28. Gao L, "Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis", Int J Neurosci, 125, pp.645~654 (2015)
29. Sako W, "Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis", Mov Disord, 29, pp.1599~1605 (2014)
30. Eusebi P, "Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson’s disease: a systematic review and meta-analysis", Mov Disord, 32, pp.1389~1400 (2017)
31. Mollenhauer B, "Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls", Neurology, 89, pp.1959~1969 (2017)
32. Hall S, "Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease", Mov Disord, 31, pp.898~905 (2016)
33. Tokuda T, "Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease", Neurology, 75, pp.1766~1772 (2010)
34. Parnetti L, "Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson’s disease", Front Aging Neurosci, 6, pp.53~ (2014)
35. Majbour NK, "Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease", Mol Neurodegener, 11, pp.7~ (2016)
36. Fujiwara H, "Alpha-synuclein is phosphorylated in synucleinopathy lesions", Nat Cell Biol, 4, pp.160~164 (2002)
37. Foulds PG, "Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease", FASEB J, 25, pp.4127~4137 (2011)
38. Stewart T, "Phosphorylated alpha-synuclein in Parkinson’s disease: correlation depends on disease severity", Acta Neuropathol Commun, 3, pp.7~ (2015)
39. Wang Y, "Phosphorylated alpha-synuclein in Parkinson’s disease", Sci Transl Med, 4, pp.121ra120~ (2012)
40. Volpicelli-Daley LA, "Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death", Neuron, 72, pp.57~71 (2011)
41. He R, "Recent advances in biomarkers for Parkinson’s disease", Front Aging Neurosci, 10, pp.305~ (2018)
42. Shahnawaz M, "Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid", JAMA Neurol, 74, pp.163~172 (2017)
43. Fairfoul G, "Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies", Ann Clin Transl Neurol, 3, pp.812~818 (2016)
44. Kang UJ, "Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson’s disease", Mov Disord, 34, pp.536~544 (2019)
45. Rossi M, "Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies", Acta Neuropathol, 140, pp.49~62 (2020)
46. Iranzo A, "Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study", Lancet Neurol, 20, pp.203~212 (2021)
47. Groveman BR, "Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC", Acta Neuropathol Commun, 6, pp.7~ (2018)
48. Shin J, "Submandibular gland is a suitable site for alpha synuclein pathology in Parkinson disease", Parkinsonism Relat Disord, 58, pp.35~39 (2019)
49. Fayyad M, "Parkinson’s disease biomarkers based on alpha-synuclein", J Neurochem, 150, pp.626~636 (2019)
50. Shin C, "Fundamental limit of alpha-synuclein pathology in gastrointestinal biopsy as a pathologic biomarker of Parkinson’s disease: comparison with surgical specimens", Parkinsonism Relat Disord, 44, pp.73~78 (2017)
51. Tsukita K, "Value of in vivo alpha-synuclein deposits in Parkinson’s disease: a systematic review and meta-analysis", Mov Disord, 34, pp.1452~1463 (2019)
52. Wang Z, "Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease", JAMA Neurol, 78, pp.1~11 (2020)
53. Manne S, "Blinded RT-QuIC analysis of alpha-synuclein biomarker in skin tissue from Parkinson’s disease patients", Mov Disord, 35, pp.2230~2239 (2020)
54. Manne S, "Alpha-synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson’s disease patients", Mov Disord, 35, pp.268~278 (2020)
55. Ballard C, "Alzheimer’s disease", Lancet, 377, pp.1019~1031 (2011)
56. Jinny Claire Lee, "Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers", Experimental and Molecular Medicine, 51, pp.1~10 (2019), 생화학분자생물학회[DOI]
57. Siderowf A, "CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease", Neurology, 75, pp.1055~1061 (2010)
58. Chojdak-Lukasiewicz J, "Plasma tau protein and Abeta42 level as markers of cognitive impairment in patients with Parkinson’s disease", Adv Clin Exp Med, 29, pp.115~121 (2020)
59. Vranová HP, "Tau protein, beta-amyloid(1)(-)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia", J Neurol Sci, 343, pp.120~124 (2014)
60. Hu X, "Changes of cerebrospinal fluid Abeta42, t-tau, and p-tau in Parkinson’s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis", Neurol Sci, 38, pp.1953~1961 (2017)
61. Compta Y, "The significance of alpha-synuclein, amyloid-beta and tau pathologies in Parkinson’s disease progression and related dementia", Neurodegener Dis, 13, pp.154~156 (2014)
62. Clinton LK, "Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline", J Neurosci, 30, pp.7281~7289 (2010)
63. Hall S, "Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and", or parkinsonian disorders, 2012, pp.69, 1445~1452
64. Liu C, "CSF tau and tau", Abeta42 predict cognitive decline in Parkinson’s disease, 2015, pp.21, 271~276
65. Chen NC, "Plasma levels of alpha-synuclein, Abeta-40 and t-tau as biomarkers to predict cognitive impairment in Parkinson’s disease", Front Aging Neurosci, 12, pp.112~ (2020)
66. Zhang J, "Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease", Acta Neuropathol, 126, pp.671~682 (2013)
67. Montine TJ, "CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment", Mov Disord, 25, pp.2682~2685 (2010)
68. Jimenez-Jimenez FJ, "Cerebrospinal fluid biochemical studies in patients with Parkinson’s disease: toward a potential search for biomarkers for this disease", Front Cell Neurosci, 8, pp.369~ (2014)
69. Mondello S, "CSF alpha-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders", Parkinsonism Relat Disord, 20, pp.382~387 (2014)
70. Parnetti L, "Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease", Mov Disord, 29, pp.1019~1027 (2014)
71. Avenali M, "Glucocerebrosidase defects as a major risk factor for Parkinson’s disease", Front Aging Neurosci, 12, pp.97~ (2020)
72. Howells DW, "Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra", Exp Neurol, 166, pp.127~135 (2000)
73. Scalzo P, "Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease", J Neurol, 257, pp.540~545 (2010)
74. Mashayekhi F, "Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease", J Clin Neurosci, 17, pp.623~627 (2010)
75. Godau J, "Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease", Arch Neurol, 68, pp.925~931 (2011)
76. Picillo M, "Serum IGF-1 is associated with cognitive functions in early, drug-naive Parkinson’s disease", PLoS One, 12, pp.e0186508~ (2017)
77. 황온유, "Role of Oxidative Stress in Parkinson’s Disease", Experimental Neurobiology, 22(1), pp.11~17 (2013), 한국뇌신경과학회
78. Ascherio A, "Urate as a predictor of the rate of clinical decline in Parkinson disease", Arch Neurol, 66, pp.1460~1468 (2009)
79. Kocer B, "Homocysteine levels in Parkinson’s disease: is entacapone effective?", Biomed Res Int, 2016, pp.7563705~ (2016)
80. Irizarry MC, "Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease", Neurology, 65, pp.1402~1408 (2005)
81. Zoccolella S, "Elevated plasma homocysteine levels in L-dopa-treated Parkinson’s disease patients with dyskinesias", Clin Chem Lab Med, 44, pp.863~866 (2006)
82. García-Moreno JM, "May serum levels of advanced oxidized protein products serve as a prognostic marker of disease duration in patients with idiopathic Parkinson’s disease?", Antioxid Redox Signal, 18, pp.1296~1302 (2013)
83. Gmitterová K, "8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases", Neurodegener Dis, 6, pp.263~269 (2009)
84. Hirayama M, "Urinary 8-hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson’s disease", Parkinsonism Relat Disord, 17, pp.46~49 (2011)
85. Waragai M, "Alpha-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson’s Disease", Int J Mol Sci, 11, pp.4257~4266 (2010)
86. Kikusato M, "The suppressive effect of dietary coenzyme Q10 on mitochondrial reactive oxygen species production and oxidative stress in chickens exposed to heat stress", Anim Sci J, 87, pp.1244~1251 (2016)
87. Sohmiya M, "Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson’s disease", J Neurol Sci, 223, pp.161~166 (2004)
88. Magdalinou NK, "A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes", J Neurol Neurosurg Psychiatry, 86, pp.1240~1247 (2015)
89. Jaffe JD, "Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification", Mol Cell Proteomics, 7, pp.1952~1962 (2008)
90. Whiteaker JR, "A targeted proteomics-based pipeline for verification of biomarkers in plasma", Nat Biotechnol, 29, pp.625~634 (2011)
91. Shi M, "Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression", Ann Neurol, 69, pp.570~580 (2011)
92. Martins M, "Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson’s disease", PLoS One, 6, pp.e25443~ (2011)
93. Vallelunga A, "Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and multiple system atrophy", Front Cell Neurosci, 8, pp.156~ (2014)
94. Chen Y, "MicroRNA-4639is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson’s disease", Front Aging Neurosci, 9, pp.232~ (2017)
95. Bäckström DC, "Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease", JAMA Neurol, 72, pp.1175~1182 (2015)
96. Liguori C, "CSF biomarkers for early diagnosis of synucleinopathies: focus on idiopathic RBD", Curr Neurol Neurosci Rep, 19, pp.3~ (2019)

관련 논문AI추천